At the end of every chromosome sits a cap of repeated DNA that gets a little shorter each time a cell divides. Those caps, telomeres, and the enzyme that can rebuild them, telomerase, earned a Nobel Prize, launched a generation of ageing research and became one of the most heavily marketed ideas in longevity science. The real biology is more interesting, and more cautious, than the marketing.
This guide explains what telomeres and telomerase are, why telomeres shorten, what that has to do with ageing and cancer, how researchers measure them, and what the evidence does and does not show for peptides such as Epitalon.
The short answer
- Telomeres are stretches of repeated DNA, TTAGGG in humans, that cap the ends of chromosomes and are guarded by a protein complex called shelterin.
- Because DNA copying cannot reach the very end of a chromosome, telomeres shorten with each cell division. When they become critically short, cells stop dividing.
- Telomerase is an enzyme, part protein and part RNA template, that adds telomere repeats back. It is active in stem cells, germ cells and most cancers, but low in most adult tissues.
- Elizabeth Blackburn, Carol Greider and Jack Szostak shared the 2009 Nobel Prize for discovering how telomeres and telomerase protect chromosomes.
- Longer is not simply better. Large genetic studies link inherited longer telomeres to a higher risk of several cancers, and claims that peptides such as Epitalon lengthen telomeres rest mainly on cell studies from one research group.
What telomeres are
Human chromosomes are long, linear strands of DNA, and their ends pose two problems. First, a cell’s repair machinery is built to treat a loose DNA end as a break and try to fix it, which would glue chromosomes together. Second, the enzymes that copy DNA cannot finish the job at the very tip of a strand, so a little is lost every time a cell divides.
Telomeres solve both problems. Each one is a run of the six-letter sequence TTAGGG, repeated many times over several thousand base pairs, wrapped in a set of proteins called shelterin. The cap hides the chromosome end from the repair machinery and acts as a buffer: the loss from each division comes out of the repeats rather than out of genes.
The Hayflick limit
In 1961, Leonard Hayflick and Paul Moorhead showed that normal human cells grown in a dish do not divide forever. After a few dozen divisions they stop, a ceiling now called the Hayflick limit. A decade later, the Russian biologist Alexey Olovnikov proposed the explanation: the end-replication problem steadily shortens chromosome ends, and when they run out, division halts. That stopped state, replicative senescence, is now a major theme in ageing research; our guide to the senolytic peptide FOXO4-DRI covers one approach to clearing senescent cells.
Telomerase, the enzyme that rebuilds them
On Christmas Day 1984, Carol Greider, then a graduate student in Elizabeth Blackburn’s laboratory, saw the first evidence of an enzyme that adds telomere repeats, using extracts of a single-celled pond organism called Tetrahymena. They published the discovery in 1985. Telomerase turned out to be a reverse transcriptase: a protein (TERT) that copies a short template carried on its own RNA (TERC) onto the chromosome end.
In the human body, telomerase is busy where cells must keep dividing, in germ cells, stem cells and activated immune cells, and much quieter in most adult tissues. Blackburn, Greider and Jack Szostak shared the 2009 Nobel Prize in Physiology or Medicine for the work.
Ageing-biology research peptides with Janoshik certificates.
Browse anti-aging and cellularTelomeres, ageing and disease
Average telomere length in white blood cells declines with age, and shorter telomeres are associated with several age-related conditions. Association is not causation, though: telomere length also varies widely between people of the same age and is influenced by genetics, sex and the measurement method.
The clearest evidence that telomeres matter comes from rare inherited telomere biology disorders, such as dyskeratosis congenita, in which mutations in telomerase or shelterin genes leave telomeres extremely short. People with these conditions can develop bone marrow failure and lung scarring, a vivid demonstration of what genuinely critical shortening does to tissues that renew themselves.
The cancer catch
Cancer cells have to divide indefinitely, and most of them do it by switching telomerase back on. In 1994, a team using a new sensitive assay found telomerase activity in the large majority of tumour samples tested but not in most normal tissues, which is why telomerase is studied as a cancer marker and drug target.
That cuts against the idea that longer telomeres are always healthier. In 2017, the Telomeres Mendelian Randomization Collaboration used inherited genetic variants as a natural experiment and found that people genetically predisposed to longer telomeres had a higher risk of several cancers, alongside a lower risk of coronary heart disease. Telomere length is a trade-off, not a dial to turn up.
Reasonably well established
- Telomeres shorten with cell division, and critical shortening stops division.
- Telomerase rebuilds telomeres and is active in most cancers.
- Inherited extreme shortening causes serious disease.
Open questions
- How much telomere shortening drives normal ageing, versus marking it.
- Whether raising telomerase can be done safely, given the cancer link.
- How to compare telomere results across different measurement methods.
How telomeres are measured
| Method | What it measures | Notes |
|---|---|---|
| qPCR (T/S ratio) | Average telomere length relative to a single-copy gene | Fast and cheap; more variable between labs |
| TRF analysis | Distribution of telomere fragment lengths on a gel | The classic reference method; needs more DNA |
| Flow-FISH | Telomere length in individual cell types | Used clinically for telomere biology disorders |
| TRAP assay | Telomerase activity, not length | The sensitive assay behind the 1994 cancer findings |
The difference between length and activity matters when reading claims. A study showing more telomerase activity in cultured cells is not the same as one showing longer telomeres, and neither is the same as evidence of a health effect in people. Our guide on how to read a peptide study covers that ladder of evidence.
Epitalon and the telomerase claims
Epitalon, the four-amino-acid peptide Ala-Glu-Asp-Gly, is the research peptide most often linked to telomeres. In a 2003 study, Vladimir Khavinson’s group in St. Petersburg reported that adding Epitalon to cultured human fibroblasts induced telomerase activity and lengthened telomeres. Related work from the same group has reported further effects in cells and animals.
Two cautions apply. Most of this evidence comes from a single research group and has had little independent replication, and none of it shows telomere lengthening, or any benefit, from Epitalon in controlled human trials. Given the cancer link above, a peptide that genuinely switched on telomerase would also need careful safety study. Our Epitalon research guide and anti-aging peptides overview go further.
EpitalonThe tetrapeptide behind the telomerase claimsView product and COA
FOXO4-DRISenescent-cell research peptideView product and COA
Research use only. Pure Peptides Canada products are laboratory reagents, not for human or veterinary use. This article summarizes published research for education and is not medical advice; nothing here suggests that any product lengthens telomeres or slows ageing in people.
Frequently asked questions
What are telomeres?
Telomeres are protective caps at the ends of chromosomes, made of the DNA sequence TTAGGG repeated many times and bound by a protein complex called shelterin. They stop chromosome ends from being treated as DNA breaks and buffer the small loss that occurs at each cell division.
What is telomerase?
Telomerase is an enzyme made of a protein (TERT) and an RNA template (TERC) that adds TTAGGG repeats to chromosome ends. It is active in stem cells, germ cells and most cancer cells, and low in most adult tissues.
Do telomeres shorten with age?
On average, yes: telomere length in white blood cells declines with age. But it varies widely between people of the same age, and shorter telomeres are a marker associated with ageing rather than proven to be its main cause.
Are longer telomeres always better?
No. Genetic studies, including a 2017 Mendelian randomization analysis, found that people predisposed to longer telomeres have a higher risk of several cancers, although a lower risk of coronary heart disease.
Can peptides lengthen telomeres?
Cell studies from Vladimir Khavinson’s group reported that Epitalon induced telomerase activity and telomere elongation in cultured human cells. That work has had little independent replication, and no controlled human trial has shown telomere lengthening or health benefits.
Who discovered telomerase?
Carol Greider and Elizabeth Blackburn discovered telomerase in 1984, publishing in 1985. With Jack Szostak, they received the 2009 Nobel Prize in Physiology or Medicine.
Ageing research, with the evidence in view
Ageing-biology research peptides with Janoshik certificates, priced in Canadian dollars and shipped tracked from inside Canada.
References
- Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43:405–413.
- Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.
- Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015.
- Telomeres Mendelian Randomization Collaboration; Haycock PC, et al. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol. 2017;3(5):636–651.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.